Gary L. Elfring

9.5k citations

93 papers · 7.9k · 2 hit papers · h-index 31

Impact in

Oncology top 1%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in

Molecular Biology 63
- Muscle Physiology and Disorders 44
- Cancer therapeutics and mechanisms 12
- RNA modifications and cancer 3
Pulmonary and Respiratory Medicine 13
- Cystic Fibrosis Research Advances 7

Co-authors: Langdon L. Miller (20 shared papers)Paula K. Locker (8 shared papers)Leonard B. Saltz (3 shared papers)Nicoletta Pirotta (5 shared papers)John Vernon Cox (3 shared papers)Charles David Blanke (1 shared paper)Malcolm J. Moore (1 shared paper)Lee S. Rosen (1 shared paper)
Journals: Neuromuscular Disorders (16 papers)Neurology (9 papers)Muscle & Nerve (8 papers)Journal of Clinical Oncology (8 papers)Journal of Cystic Fibrosis (7 papers)
Partner nations: United States United Kingdom France

In The Last Decade

Gary L. Elfring

88 papers receiving 7.5k citations

Gary L. Elfring's Hit Papers

align trajectories log scale

Ataluren treatment of patients with nonsense mutation dystrophinopathy 2014 · 343 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2014 Muscle & Nerve
2000 New England Journal of Medicine

Peers

Countries citing papers authored by Gary L. Elfring

Since Specialization

Citations

This map shows the geographic impact of Gary L. Elfring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary L. Elfring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary L. Elfring more than expected).

Fields of papers citing papers by Gary L. Elfring

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary L. Elfring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary L. Elfring. The network helps show where Gary L. Elfring may publish in the future.

Co-authors

The 25 scholars most cited alongside Gary L. Elfring, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gary L. Elfring Line = papers co-authored together Gary L. Elfring links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 93 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer New England Journal of Medicine ·Leonard B. Saltz, John Vernon Cox, Charles David Blanke, Lee S. Rosen, Louis Fehrenbacher, Malcolm J. Moore, Jean Alfred Maroun, Stephen P. Ackland Hit paper breakdown →	2000	2540
2	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial The Lancet ·Craig M. McDonald, Craig Campbell, Ricardo Erazo Torricelli, Richard S. Finkel, Kevin M. Flanigan, Nathalie Goemans, Peter T Heydemann, Anna Kamińska	2017	370
3	Ataluren treatment of patients with nonsense mutation dystrophinopathy Muscle & Nerve ·Katharine M. D. Bushby, Richard S. Finkel, Brenda L. Y. Wong, Richard J. Barohn, Craig Campbell, Giacomo P. Comi, Anne M. Connolly, Kevin M. Flanigan Hit paper breakdown →	2014	343
4	The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy Muscle & Nerve ·Craig M. McDonald, Erik Henricson, Jay J. Han, Richard Ted Abresch, Alina Nicorici, Gary L. Elfring, Leone Atkinson, A. Reha	2009	338
5	Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial The Lancet ·Eitan Kerem, Samit Hirawat, Shoshana Armoni, Yasmin Yaakov, David Shoseyov, Michael Cohen, Malka Nissim‐Rafinia, Hannah Blau	2008	327
6	Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. Journal of Clinical Oncology ·Mace L. Rothenberg, John Randall Eckardt, John G. Kuhn, Howard A. Burris, J. NELSON, Susan Galloway Hilsenbeck, G I Rodriguez, Allison Thurman	1996	321
7	Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma Journal of Clinical Oncology ·Henry S. Friedman, William P. Petros, Allan H. Friedman, Larry J. Schaaf, Tracy Kerby, Jennifer Lawyer, Mary Parry, Peter John Houghton	1999	301
8	Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer Journal of Clinical Oncology ·Marc E Buyse, Tomasz Burzykowski, Kevin J. Carroll, Stefan Michiels, Daniel J. Sargent, Langdon L. Miller, Gary L. Elfring, Jean‐Pierre Pignon	2007	297
9	Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial The Lancet Respiratory Medicine ·Eitan Kerem, Michael W. Konstan, K. De Boeck, Frank J. Accurso, Isabelle Sermet‐Gaudelus, Michael A. Wilschanski, J. Stuart Elborn, Paola Melotti	2014	290
10	THE 6‐minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study Muscle & Nerve ·Craig M. McDonald, Erik Henricson, Richard Ted Abresch, Julaine M Florence, Michelle Eagle, Eduard Gappmaier, Allan M. Glanzman, Robert J. Spiegel	2013	268
11	Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single‐ and Multiple‐Dose Administration to Healthy Male and Female Adult Volunteers The Journal of Clinical Pharmacology ·Samit Hirawat, Ellen M. Welch, Gary L. Elfring, Valerie J. Northcutt, Sergey V. Paushkin, Seongwoo Hwang, Eileen M. Leonard, Neil G. Almstead	2007	206
12	Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis American Journal of Respiratory and Critical Care Medicine ·Isabelle Sermet‐Gaudelus, K. De Boeck, Georges Jacques Casimir, François L. Vermeulen, Teresinha Leal, Agnès Mogenet, Delphine Behr Roussel, Janine Fritsch	2010	205
13	Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy PLoS ONE ·Richard S. Finkel, Kevin M. Flanigan, Brenda L. Y. Wong, Carsten G. Bönnemann, Jacinda B. Sampson, Hugh Lee Sweeney, A. Reha, Valerie J. Northcutt	2013	194
14	A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma Cancer ·Mace L. Rothenberg, John Vernon Cox, Russell F. DeVore, John Daniel Hainsworth, Richard M. Pazdur, Saul E. Rivkin, John Smyth Macdonald, Charles Edward Geyer Jr	1999	175
15	Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis European Respiratory Journal ·Michael A. Wilschanski, L.L. Miller, David Shoseyov, H. Blau, Joseph Rivlin, Micha Aviram, Michael Cohen, Shoshana Armoni	2011	167
16	The 6‐minute walk test in Duchenne/Becker muscular dystrophy: Longitudinal observations Muscle & Nerve ·Craig M. McDonald, Erik Henricson, Jay J. Han, Richard Ted Abresch, Alina Nicorici, Leone Atkinson, Gary L. Elfring, A. Reha	2010	148
17	Irinotecan Plus Fluorouracil/Leucovorin for Metastatic Colorectal Cancer: A New Survival Standard The Oncologist ·Leonard B. Saltz, Jean‐Yves Douillard, Nicoletta Pirotta, May Alakl, Gabriela Gruia, Lucile Awad, Gary L. Elfring, Paula K. Locker	2001	124
18	Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen Cancer ·Timothy Francis Cloughesy, Emese Filka, John G. Kuhn, Gillian Nelson, Fairooz F. Kabbinavar, Henry S. Friedman, Langdon L. Miller, Gary L. Elfring	2003	102
19	Corticosteroids in Duchenne muscular dystrophy: Major variations in practice Muscle & Nerve ·Robert C. Griggs, Barbara Evelyn Herr, A. Reha, Gary L. Elfring, Leone Atkinson, Valerie A. Cwik, Elaine McColl, Rabi Tawil	2013	91
20	Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients With Solid Tumors Journal of Clinical Oncology ·Ronald L. Drengler, John G. Kuhn, Larry J. Schaaf, Gladys Rodriguez, Miguel Angel Villalona-Calero, Lisa A. Hammond, Joseph Stephenson, Stephanie Hodges	1999	87

About Gary L. Elfring

Gary L. Elfring is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Oncology, Cardiology and Cardiovascular Medicine and Cell Biology, having authored 93 papers that have together received 7.9k indexed citations. Recurring topics across this work include Muscle Physiology and Disorders (44 papers), Cancer therapeutics and mechanisms (12 papers), Cystic Fibrosis Research Advances (7 papers), Biotin and Related Studies (6 papers), Cardiomyopathy and Myosin Studies (6 papers), Statistical Methods in Clinical Trials (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and RNA modifications and cancer (3 papers). The work is most often cited by research in Oncology (2.6k citations), Hepatology (732 citations), Genetics (848 citations), Pulmonary and Respiratory Medicine (1.5k citations) and Molecular Biology (3.3k citations). Gary L. Elfring has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Langdon L. Miller, Paula K. Locker, Leonard B. Saltz, Nicoletta Pirotta, John Vernon Cox, Charles David Blanke, Malcolm J. Moore, Lee S. Rosen, Louis Fehrenbacher and Jean Alfred Maroun. Their work appears in journals such as Neuromuscular Disorders, Neurology, Muscle & Nerve, Journal of Clinical Oncology and Journal of Cystic Fibrosis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Gary L. Elfring

Impact in

Papers in i

In The Last Decade

Gary L. Elfring

Gary L. Elfring's Hit Papers

Peers

Countries citing papers authored by Gary L. Elfring

Fields of papers citing papers by Gary L. Elfring

All Works

About Gary L. Elfring

Explore authors with similar magnitude of impact

Papers in